Readiness Program
FDA Regulatory Readiness & Submission Support
Executive level regulatory strategy and hands-on submission support, led by senior experts who have sat on both sides of the FDA table.
Looking for an FDA regulatory consultant? PXM operators work inside your team.
PXM is a life-science venture and transactions firm. Our senior regulatory operators, including former FDA reviewers, join your leadership team to own the FDA pathway, agency meetings and submissions, accountable for the outcome rather than delivering a report from the outside.
Compare FDA expedited pathwaysRegulatory Strategy That Holds Up Under Review
Most regulatory problems in biotech are not discovered at submission. They are created 12 to 24 months earlier, in decisions about development pathway, comparability, dose justification, and the evidence a program plans to generate. By the time FDA responds, the cost of correction is measured in quarters, not weeks.
PXM provides senior FDA regulatory support across the full arc of a program: choosing and defending a regulatory pathway, preparing agency meetings, assembling and reviewing submissions, and responding to information requests, deficiencies, and holds. Our senior experts include former agency reviewers and industry regulatory leads who have taken products from first-in-human through approval.
We work as an extension of the leadership team rather than a document factory. That means being in the room for the strategic calls, and being accountable for how those calls read to a reviewer.
What We Deliver
Regulatory Pathway Strategy
Selection and justification of the development and approval pathway, including expedited program eligibility such as Fast Track, Breakthrough, RMAT, and orphan designation.
FDA Meeting Preparation
Pre-IND, Type B, Type C, and Type D meetings: question framing, briefing book authoring, internal rehearsal, and follow up on agency minutes.
Submission Support
Strategic input and senior review across IND, BLA, NDA, and amendment modules, with a focus on regulatory coherence rather than page count.
Agency Correspondence
Information request responses, deficiency letters, complete response letters, and clinical hold remediation plans.
Designation Applications
Orphan drug, rare pediatric disease, Fast Track, and Breakthrough Therapy applications, positioned against real precedent.
Regulatory Due Diligence
Independent assessment of regulatory risk for investors, boards, and licensing partners ahead of a financing or transaction.
Who This Is For
- Biotech companies preparing a first FDA interaction and without in-house regulatory leadership
- Programs that have received FDA feedback, an information request, or a clinical hold and need to respond quickly
- Companies developing novel modalities where precedent is thin and the pathway must be argued rather than cited
- Non-US companies entering the US market and calibrating an existing EU or UK dossier to FDA expectations
- Investors and boards seeking independent regulatory diligence before a financing or license deal
How We Work
Assess
Review of the program, existing data, prior agency interactions, and the gap between the current package and what a reviewer will expect.
Position
Definition of the regulatory pathway, the agency engagement plan, and the specific questions worth asking FDA now versus later.
Prepare
Briefing books, submission modules, and response documents drafted and senior reviewed, with rehearsal ahead of any live agency meeting.
Sustain
Ongoing regulatory support through review cycles, amendments, and the next development milestone.
Frequently Asked Questions
FDA & CMC Readiness
Guides and insights
What a Clinical Overview Must Contain for an EU Hybrid Application
What the Clinical Overview (Module 2.5) must cover in an EU hybrid application under Article 10(3), how to justify differences from the reference product, and where assessors push back.
Read the guide →Well-Established Use Applications: Building a Bibliographic Clinical Overview That Holds Up
How to build the Clinical Overview for an EU well-established use application under Article 10a: the ten-year test, literature selection, and how to bridge your product to the published evidence.
Read the guide →How to Choose an Independent Clinical Expert for Your EU Dossier
What Article 12 of Directive 2001/83/EC requires from the Clinical and Nonclinical Expert, what to look for when you appoint one, and the questions to ask before they sign.
Read the guide →FDA National Priority Voucher (CNPV): Should You Apply?
What the FDA national priority voucher (CNPV) offers in 2026, how it compares to other expedited programs, and what EU sponsors need ready first.
Read the guide →Your CDMO Just Became a Regulatory Risk: BIOSECURE and FDA PreCheck Explained
The BIOSECURE Act is law and the FDA's PreCheck pilot has named its first participants. Both change how EU biotechs should screen, select, and oversee US CDMOs and CROs.
Read the guide →How to Prepare for an FDA Pre-IND Meeting (and What Most Teams Get Wrong)
A pre-IND meeting is the cheapest regulatory advice a biotech will ever get, and the most commonly wasted. What to ask, what to include in the briefing book, and where teams lose the value.
Read the guide →IND-Enabling Studies: What a First-in-Human Package Actually Requires
What IND-enabling studies are, which ones the FDA expects before first-in-human, how long the package takes, and the sequencing decisions that quietly determine your filing date.
Read the guide →CDMO Selection for Biotech: The Criteria That Actually Predict Success
Choosing a CDMO is a regulatory decision, not a procurement one. The criteria that matter, the questions to ask before signing, and the contract terms teams regret leaving out.
Read the guide →5 CMC Strategy Mistakes That Delay IND Filings — And How to Avoid Them
Common chemistry, manufacturing, and controls pitfalls that quietly derail small biotech IND timelines, and the practical fixes that keep programs on track.
Read the guide →3 Regulatory Mistakes That Keep Coming Up in Biotech
After several recent conversations with biotech and digital health teams, a pattern keeps repeating. Not around the science — that's usually strong. It's around regulation.
Read the guide →Bluebird Bio's Three-Year FDA Delay: The CMC Trap That Stalls Gene Therapy Programs
Bluebird Bio almost didn't survive the road to FDA approval — not because the science wasn't there, but because of CMC comparability gaps and pediatric safety signals that weren't built into the development plan. The same patterns are stalling programs today.
Read the guide →UK Biotech Companies: How to Navigate EU and US Market Entry Post-Brexit
Brexit has fundamentally reshaped the regulatory and commercial landscape for UK biotech companies. Navigating parallel pathways across the MHRA, EMA, and FDA requires a new level of strategic coordination — and the companies that adapt fastest will capture the greatest opportunity.
Read the guide →Cell Therapy Companies: Manufacturing May Become Your Biggest Bottleneck
Many biotech teams focus heavily on discovery and clinical data. But regulators are increasingly asking a different question: Can you manufacture your therapy consistently and at scale?
Read the guide →A Regulatory Inflection Point for Biologics – Will You Lead or React?
The FDA's recent announcement signals a meaningful shift in how biologics and ultra-rare disease therapies may be evaluated — including openness to smaller, well-justified data packages.
Read the guide →
Ready to discuss your program?
Speak with a senior PXM operator about your fda regulatory affairs & submission support strategy.